Table 1 Overview of the inclusion and exclusion criteria of the MinTU study

• Patients receiving specialized palliative care on the palliative care ward at study site

• Impaired nasal absorption or no possibility for subcutaneous application

• Patients aged 18 years or older

• Patients with hypersensitivity to midazolam

• Capacity to give consent: Participants must be able to understand the nature and scope of the clinical trial.

• Patients who have taken midazolam within the past 24 h

• Dying Patients in the terminal phase of their illness

• Intake of strong CYP 3A4 inducers/inhibitors

• Patients experiencing terminal agitation

• Other causes of agitation

• RASS PAL Score greater than 0

• Sufficient effectiveness of non-drug interventions